In that paper, they speculate that reduced levels of molecules involved in BBB disruption, such as MMP-9, could interfere with CD8+ T-lymphocyte immune surveillance mechanisms in the CNS, predisposing MS patients to JCV reactivation and PML development23. The gene discussed is MMP9; the disease is myeloid sarcoma.